Raymond Debbane, Director at LEXICON PHARMACEUTICALS, INC. (LXRX), bought 268,497 shares at $1.31 ($353K) on 2026-02-17, disclosed to the SEC on 2026-02-18.
Open-market purchase of $353k LXRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.31 | 57,952 | $76K | 21.5% |
| 2 | $1.31 | 76,857 | $101K | 28.5% |
| 3 | $1.32 | 133,688 | $176K | 50.0% |
| Total | $1.31 avg | 268,497 | $353K | 100% |
| Filing → |
| LXRX | BUY | 2026-02-23 | $220K | — | Filing → |
| LXRX | BUY | 2023-10-12 | $2.2M | — | Filing → |
| WW | BUY | 2022-11-15 | $641K | — | Filing → |